Sign In
Buy UTHR
$549.47
+9.42 (+1.74%)
At Close: Jun 03, 2026
Charles Schwab Investment Management Inc. Decreases Holdings in United Therapeutics Corporation $UTHR
04:22am, Saturday, 29'th Nov 2025
Charles Schwab Investment Management Inc. reduced its holdings in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 4.3% in the undefined quarter, according to the company in its most recent
United Therapeutics Corporation $UTHR Position Boosted by AXQ Capital LP
05:14am, Saturday, 22'nd Nov 2025
AXQ Capital LP grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 495.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Ex
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
10:46am, Thursday, 20'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript
10:38am, Tuesday, 18'th Nov 2025
United Therapeutics Corporation ( UTHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:00 AM EST Company Participants Harrison Silvers - Manager of Investor Relations James Edgemond
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 12'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript
02:01pm, Monday, 10'th Nov 2025
United Therapeutics Corporation ( UTHR ) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Patrick Poisson - Executive VP of Technical Operations Conference Call
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
10:40am, Wednesday, 05'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 04'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics Corporation to Present at Upcoming Investor Conferences
07:00am, Tuesday, 04'th Nov 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide a
World Investment Advisors Trims Stock Position in United Therapeutics Corporation $UTHR
04:17am, Tuesday, 04'th Nov 2025
World Investment Advisors decreased its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 40.2% during the undefined quarter, according to the company in its most recent disclosu
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its EXPAND study of the UKi
MKKGY vs. UTHR: Which Stock Is the Better Value Option?
12:41pm, Thursday, 30'th Oct 2025
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
04:42am, Thursday, 30'th Oct 2025
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, October 27th. The shares were so
United Therapeutics (NASDAQ:UTHR) CEO Sells $1,696,240.00 in Stock
04:42am, Thursday, 30'th Oct 2025
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark
12:26pm, Wednesday, 29'th Oct 2025
UTHR beats Q3 earnings forecasts on solid Tyvaso and Orenitram growth, while revenues fall shy of estimates.
